.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP07_Daclatasvir.Daclatasvir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP07_Daclatasvir.Daclatasvir| name: | Daclatasvir |
| ATC code: | J05AP07 | route: | oral |
| n-compartments | 2 |
Daclatasvir is a direct-acting antiviral medication that acts as an inhibitor of the HCV NS5A protein, thereby inhibiting hepatitis C virus (HCV) replication. It is approved for use, often in combination with other antivirals, for the treatment of chronic HCV infection in adults.
Population pharmacokinetics in healthy adult subjects (sex not specified) after single oral dose.
Osawa, M, et al., & Garimella, T (2019). Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects. Clinical pharmacology in drug development 8(6) 802–817. DOI:10.1002/cpdd.649 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30629858
Al-Nahari, MM, et al., & Farid, SF (2020). Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection. Antiviral therapy 25(2) 101–110. DOI:10.3851/IMP3357 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32367815
Osawa, M, et al., & Garimella, T (2018). Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection. Journal of clinical pharmacology 58(11) 1468–1478. DOI:10.1002/jcph.1274 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30063254